Alpha DNA Investment Management LLC Buys Shares of 9,023 Trupanion, Inc. (NASDAQ:TRUP)

Alpha DNA Investment Management LLC acquired a new stake in shares of Trupanion, Inc. (NASDAQ:TRUP - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 9,023 shares of the financial services provider's stock, valued at approximately $435,000.

Several other hedge funds have also recently modified their holdings of TRUP. SBI Securities Co. Ltd. bought a new stake in Trupanion during the fourth quarter worth approximately $25,000. Jones Financial Companies Lllp raised its holdings in shares of Trupanion by 71.7% in the fourth quarter. Jones Financial Companies Lllp now owns 570 shares of the financial services provider's stock valued at $27,000 after acquiring an additional 238 shares in the last quarter. Aster Capital Management DIFC Ltd boosted its position in Trupanion by 988.5% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 1,132 shares of the financial services provider's stock valued at $55,000 after acquiring an additional 1,028 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Trupanion in the 3rd quarter worth approximately $54,000. Finally, KBC Group NV purchased a new position in Trupanion during the 4th quarter worth $75,000.

Trupanion Price Performance

TRUP traded up $0.70 during midday trading on Wednesday, hitting $35.68. 551,753 shares of the company traded hands, compared to its average volume of 654,010. The business has a 50 day simple moving average of $36.18 and a two-hundred day simple moving average of $45.44. Trupanion, Inc. has a 52-week low of $19.69 and a 52-week high of $57.90. The company has a current ratio of 1.71, a quick ratio of 1.66 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -155.13, a PEG ratio of 6.02 and a beta of 1.66.

Trupanion (NASDAQ:TRUP - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The financial services provider reported $0.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.02). The firm had revenue of $337.31 million for the quarter, compared to analyst estimates of $335.41 million. Trupanion had a negative return on equity of 3.08% and a negative net margin of 0.75%. On average, equities analysts forecast that Trupanion, Inc. will post 0.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Fawwad Qureshi sold 1,373 shares of the stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $34.22, for a total value of $46,984.06. Following the transaction, the chief financial officer now owns 2,416 shares in the company, valued at approximately $82,675.52. This represents a 36.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Margaret Tooth sold 4,000 shares of Trupanion stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $37.17, for a total value of $148,680.00. Following the transaction, the chief executive officer now directly owns 118,784 shares in the company, valued at approximately $4,415,201.28. This trade represents a 3.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,792 shares of company stock worth $989,442 over the last 90 days. 5.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

TRUP has been the topic of a number of research reports. Piper Sandler cut their price objective on Trupanion from $57.00 to $52.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Stifel Nicolaus decreased their target price on shares of Trupanion from $44.00 to $41.00 and set a "hold" rating for the company in a research report on Thursday, February 20th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Trupanion presently has an average rating of "Moderate Buy" and a consensus target price of $46.60.

Trupanion Profile

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.